https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2025-02-13 09:57:572025-02-13 09:57:57Cytovation Appoints Martin Dewhurst to its Board of Directors
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2025-01-23 09:52:202025-01-23 09:55:46Cancer Research UK, Cytovation and the Norwegian Cancer Society collaborate to advance treatment for rare cancer
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2024-09-16 09:18:092024-09-21 21:54:04Cytovation to present full safety and efficacy data from the CICILIA Phase I/IIa trial evaluating CY-101 in solid tumors at ESMO 2024
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2023-12-21 13:33:012023-12-21 13:33:34Cytovation Announces Appointment of Ellen Lubman, MBA to its Board of Directors
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2023-10-11 10:04:332025-01-23 09:55:52Cytovation Reports Promising Interim Results from Phase 1/2a CICILIA Study with CyPep-1 in Solid Tumors
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2023-08-01 19:05:522023-08-01 19:05:52Cytovation appoints Olav Hellebø to its Board of Directors
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2023-06-05 12:09:472023-06-05 12:11:02Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapy
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2023-04-12 11:11:572023-04-24 14:45:30Cytovation appoints Iman Barilero as Chief Development Officer
https://www.cytovation.com/wp-content/uploads/2020/05/Logoicon-1.jpg500500Therese Nessehttps://www.cytovation.com/wp-content/uploads/2022/01/Cytovation-Logo-1.pngTherese Nesse2023-02-17 09:02:112023-02-17 09:04:10Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors
